Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

141. The Use of a Recombinant Canarypox-Based Equine Influenza Vaccine during the 2007 Australian Outbreak: A Systematic Review and Summary. (PubMed)

The Use of a Recombinant Canarypox-Based Equine Influenza Vaccine during the 2007 Australian Outbreak: A Systematic Review and Summary. In 2007, Australia experienced the most extensive equine influenza outbreak observed in recent years. Extraordinary measures were rapidly implemented in order to control and prevent the spread of this highly contagious disease. The control strategy involved stringent movement restriction and disease surveillance, seconded by emergency post-outbreak vaccination (...) strategies. Sixteen months after the first case and 12 months following the last reported case, Australia regained its equine influenza-free OIE status. This systematic review reports and summarises information relating to the implementation of emergency vaccination during the 2007 Australian equine influenza outbreak, including the choice of vaccine and implementation strategies.

Full Text available with Trip Pro

2016 Pathogens (Basel, Switzerland)

142. Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions. (PubMed)

Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions. A systematic review found that 3% of working adults who had received influenza vaccine and 5% of those who were unvaccinated had laboratory-proven influenza per season; in healthcare workers (HCWs) these percentages were 5% and 8% respectively. Healthcare workers may transmit influenza to patients.To identify all randomised controlled trials (RCTs) and non-RCTs assessing (...) the effects of vaccinating healthcare workers on the incidence of laboratory-proven influenza, pneumonia, death from pneumonia and admission to hospital for respiratory illness in those aged 60 years or older resident in long-term care institutions (LTCIs).We searched CENTRAL (2015, Issue 9), MEDLINE (1966 to October week 3, 2015), EMBASE (1974 to October 2015) and Web of Science (2006 to October 2015), but Biological Abstracts only from 1969 to March 2013 and Science Citation Index-Expanded from 1974

2016 Cochrane

143. Seasonal Influenza Infections and Cardiovascular Disease Mortality (PubMed)

Seasonal Influenza Infections and Cardiovascular Disease Mortality Cardiovascular deaths and influenza epidemics peak during winter in temperate regions.To quantify the temporal association between population increases in seasonal influenza infections and mortality due to cardiovascular causes and to test if influenza incidence indicators are predictive of cardiovascular mortality during the influenza season.Time-series analysis of vital statistics records and emergency department visits in New (...) York City, among cardiovascular deaths that occurred during influenza seasons between January 1, 2006, and December 31, 2012. The 2009 novel influenza A(H1N1) pandemic period was excluded from temporal analyses.Emergency department visits for influenza-like illness, grouped by age (≥0 years and ≥65 years) and scaled by laboratory surveillance data for viral types and subtypes, in the previous 28 days.Mortality due to cardiovascular disease, ischemic heart disease, and myocardial infarction.Among

Full Text available with Trip Pro

2016 JAMA cardiology

144. Pandemic influenza vaccine H5N1 MedImmune

Pandemic influenza vaccine H5N1 MedImmune 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 01 April 2016 EMA/CHMP/323530/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pandemic influenza vaccine H5N1 MedImmune Common name: pandemic influenza vaccine (H5N1) (live attenuated, nasal) Procedure No. EMEA (...) aminotransferase ANC absolute neutrophil count AOM acute otitis media ASC antibody secreting cell AST aspartate aminotransferase att attenuated ca cold-adapted CAIV-T influenza virus vaccine, trivalent, types A and B, live cold-adapted CDC Centers for Disease Control and Prevention CI confidence interval CMI cell-mediated immunity CSR clinical study report CRADA cooperative research and development agreement CTL cytotoxic T-lymphocyte DOD Department of Defense ELISA enzyme-linked immunosorbent assay ELISPOT

2016 European Medicines Agency - EPARs

145. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data

Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data Neuraminidase inhibitors for influenza: a systematic review and meta- analysis of regulatory and mortality data Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information (...) of Regulatory and Mortality Data for Zanamivir (Relenza) and Oseltamivir (Tamiflu) The authors of a new review of the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir (Tamiflu) found that these drugs minimally shorten the duration of influenza-like illness by about a day and that oseltamivir did not affect the number of hospitalizations. [1] The new review [1] confirmed a previous review done by many of the same authors in 2014 [2] and the FDA’s definitive reviews of these drugs done in 1999

2016 NIHR HTA programme

146. Interventions in live poultry markets for the control of avian influenza: a systematic review. (PubMed)

Interventions in live poultry markets for the control of avian influenza: a systematic review. 27213177 2018 11 13 2352-7714 2 2016 Dec One health (Amsterdam, Netherlands) One Health Interventions in live poultry markets for the control of avian influenza: a systematic review. 55-64 Offeddu Vittoria V WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative (...) Region, China. Cowling Benjamin J BJ WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China. Malik Peiris J S JS WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Centre of Influenza Research

Full Text available with Trip Pro

2016 One health

147. Antiviral activity of the oseltamivir and Melissa officinalis L. essential oil against avian influenza A virus (H9N2) (PubMed)

Antiviral activity of the oseltamivir and Melissa officinalis L. essential oil against avian influenza A virus (H9N2) Lemon balm derivatives are going to acquire a novelty as natural and potent remedy for treatment of viral infections since the influenza viruses are developing resistance to the current antivirals widely. Oseltamivir, Melissa officinalis essential oil (MOEO) and their synergistic efficacy against avian influenza virus (AIV) subtype H9N2 were evaluated in vitro in MDCK cells (...) and Its main constituents were identified as monoterpenaldehydes citral a, citral b. In conclusion, the findings of the study showed that lemon balm essential oil could inhibit influenza virus replication through different replication cycle steps especially throughout the direct interaction with the virus particles.

Full Text available with Trip Pro

2016 Virusdisease

148. Concordance of interim and final estimates of influenza vaccine effectiveness: a systematic review. (PubMed)

Concordance of interim and final estimates of influenza vaccine effectiveness: a systematic review. The World Health Organization's Global Influenza Surveillance and Response System meets twice a year to generate a recommendation for the composition of the seasonal influenza vaccine. Interim vaccine effectiveness (VE) estimates provide a preliminary indication of influenza vaccine performance during the season and may be useful for decision making. We reviewed 17 pairs of studies reporting 33 (...) estimates was found for 18 of 33 reported pairs of estimates, including six of 12 pairs reporting VE against any influenza, six of 10 for influenza A(H1N1)pdm09, four of seven for influenza A(H3N2) and two of four for influenza B. While we identified inconsistencies in the methods, the similarities between interim and final estimates support the utility of generating and disseminating preliminary estimates of VE while virus circulation is ongoing.

Full Text available with Trip Pro

2016 Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin

149. The emergence and consistency of influenza strains causing influenza like illness in Himachal Pradesh, India (PubMed)

The emergence and consistency of influenza strains causing influenza like illness in Himachal Pradesh, India The present study offers the status of ongoing surveillance influenza at National Influenza Surveillance Centre (NISC), Central Research Institute (CRI), Kasauli for the emergence and consistency of influenza strains for current as well as over a period of three decades in Solan, Himachal Pradesh. From 1980 to 2015, various clinical centers of Himachal reported counts of influenza-like (...) illness (fever including cough or sore throat). During these years, the respiratory specimens of 6581 patients showing influenza-like illness were collected. The incidence of visits had been calculated for influenza-like illness using the size of the patient population, and the incidence attributable to influenza was extrapolated from the proportion of patients with positive tests. Up to 2008 the egg inoculation method was used for the isolation and detection of influenza strains but in 2009 a RT-PCR

Full Text available with Trip Pro

2016 Virusdisease

150. Oseltamivir (Tamiflu) - for the treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza

Oseltamivir (Tamiflu) - for the treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza Final Appraisal Recommendation Advice No: 0316 – February 2016 Oseltamivir (Tamiflu ® ) 30 mg, 45 mg and 75 mg capsules, and 6 mg/ml powder for oral suspension Limited submission by Roche Products Ltd Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above (...) including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.

2016 All Wales Medicines Strategy Group

151. Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients: A Cohort Study. (PubMed)

Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients: A Cohort Study. Despite recommendations to vaccinate surgical inpatients against influenza, vaccination rates remain low in this population, due in part to concerns about potential negative effects on postsurgical care.To evaluate whether influenza vaccination in the perioperative period increases health care utilization and evaluations for postsurgical infection after discharge.Retrospective cohort study.Members (...) of Kaiser Permanente Southern California.Patients aged 6 months or older who had inpatient surgery with admission and discharge between 1 September and 31 March from 2010 to 2013.All influenza vaccinations administered between 1 August and 30 April in the 2010-2011, 2011-2012, and 2012-2013 influenza seasons. Outcomes included rates of outpatient visits, readmission, emergency department (ED) visits, fever (temperature ≥38.0 °C), and clinical laboratory evaluations for infection (urine culture, complete

2016 Annals of Internal Medicine

152. Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans l’hémisphère Nord

Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans l’hémisphère Nord Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans l’hémisphère (...) Nord JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans l’hémisphère Nord View/ Open View Statistics Altmetrics Share Citation World Health Organization

2016 WHO

153. Influenza: from zoonosis to pandemic (PubMed)

Influenza: from zoonosis to pandemic Global surveillance and advances in vaccine technology are essential to answer the threat of influenza pandemics http://ow.ly/Yt3e4.

Full Text available with Trip Pro

2016 ERJ open research

154. Corticosteroids as adjunctive therapy in the treatment of influenza. (PubMed)

Corticosteroids as adjunctive therapy in the treatment of influenza. Specific treatments for influenza are limited to neuraminidase inhibitors and adamantanes. Corticosteroids show evidence of benefit in sepsis and related conditions, most likely due to their anti-inflammatory and immunomodulatory properties. Although commonly prescribed for severe influenza, there is uncertainty over their potential benefit or harm.To systematically assess the effectiveness and potential adverse effects (...) of corticosteroids as adjunctive therapy in the treatment of influenza, taking into account differences in timing and doses of corticosteroids.We searched CENTRAL (2015, Issue 5), MEDLINE (1946 to June week 1, 2015), EMBASE (1974 to June 2015), CINAHL (1981 to June 2015), LILACS (1982 to June 2015), Web of Science (1985 to June 2015), abstracts from the last three years of major infectious disease and microbiology conferences, and references of included articles.We included randomised controlled trials (RCTs

Full Text available with Trip Pro

2016 Cochrane

155. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. (PubMed)

Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cystic fibrosis is the most common, life-threatening, recessively inherited disease of Caucasian populations. It is a multisystem disorder caused by a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator protein which is important in producing sweat, digestive juices and mucus.The impaired or absent function of this protein results in the production of viscous mucus (...) within the lungs and an environment that is susceptible to chronic airway obstruction and pulmonary colonization by a range of pathogenic bacteria. Morbidity and mortality of cystic fibrosis is related to chronic pulmonary sepsis and its complications by these bacteria.Influenza can worsen the course of the disease in cystic fibrosis by increasing the risk of pneumonia and secondary respiratory complications. Antiviral agents form an important part of influenza management and include

2016 Cochrane

156. Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. (PubMed)

Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. People affected with sickle cell disease are at high risk of infection from Haemophilus influenzae type b. Before the implementation of Haemophilus influenzae type b conjugate vaccination in high-income countries, this was responsible for a high mortality rate in children under five years of age. In African countries, where coverage of this vaccination is still extremely low, Haemophilus influenzae type b remains one (...) of the most common cause of bacteraemias in children with sickle cell disease. The increased uptake of this conjugate vaccination may substantially improve the survival of children with sickle cell disease.The primary objective was to determine whether Haemophilus influenzae type b conjugate vaccines reduce mortality and morbidity in children and adults with sickle cell disease.The secondary objectives were to assess the following in children and adults with sickle cell disease: the immunogenicity

Full Text available with Trip Pro

2016 Cochrane

157. Probable Hospital Cluster of H7N9 Influenza Infection. (PubMed)

Probable Hospital Cluster of H7N9 Influenza Infection. 26863372 2016 02 24 2017 04 06 1533-4406 374 6 2016 02 11 The New England journal of medicine N. Engl. J. Med. Probable Hospital Cluster of H7N9 Influenza Infection. 596-8 10.1056/NEJMc1505359 Farooqui Amber A Shantou University Medical College, Shantou, China. Liu Weidong W Second Affiliated Hospital, Shantou, China. Zeng Tiansheng T Shantou University Medical College, Shantou, China. Liu Yisu Y Shantou University Medical College, Shantou (...) of Infection and Immunity, Shantou, China. dkelvin@jidc.org H7N9 Shantou Working Group eng Letter Research Support, Non-U.S. Gov't United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2016 Sep 8;375(10):e23 27602686 N Engl J Med. 2016 Sep 8;375(10):e23 27602687 Adult China Cross Infection Hospitals, University Humans Infectious Disease Transmission, Patient-to-Professional Influenza A Virus, H7N9 Subtype genetics isolation & purification Influenza, Human transmission virology Male Phylogeny

2016 NEJM

158. Characterization of evolutionary changes in hemagglutinin of influenza H1N1 virus: a computational analysis (PubMed)

Characterization of evolutionary changes in hemagglutinin of influenza H1N1 virus: a computational analysis Influenza virus continues to evolve due to changes in the genome and the new strain of virus is more pathogenic then the previous strain. These changes may also help the virus to cross specie barrier and may also affect the binding pattern of virus.The main theme of the current study is the identification of changes in the hemagglutinin sequence of H1N1 virus from 1960 to 2011 and also

Full Text available with Trip Pro

2016 Virusdisease

159. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits Report by the Director-GeneralPandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Di

Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits Report by the Director-GeneralPandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Di Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle (...) navigation Toggle navigation Search Browse Statistics Related Links Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General View/ Open View Statistics Altmetrics Share Citation World Health Assembly, 69 . (‎2016)‎. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General. World Health Organization. Gov't Doc # A69/22 Collections Language English

2016 WHO

160. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Special Session of the Pandemic Influenza Preparedness Framework Advisory Group

Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Special Session of the Pandemic Influenza Preparedness Framework Advisory Group Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Special Session of the Pandemic Influenza Preparedness Framework Advisory Group JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle (...) navigation Toggle navigation Search Browse Statistics Related Links Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Special Session of the Pandemic Influenza Preparedness Framework Advisory Group View/ Open View Statistics Altmetrics Share Citation World Health Assembly, 69 . (‎2016)‎. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Special Session of the Pandemic

2016 WHO